# Treatment of Moderate to Severe Glabellar Lines

> **NCT04249583** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 300 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** botulinum toxin
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04249583
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-10
- **Primary completion:** 2020-08-07
- **Final completion:** 2021-01-05
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249583, "Treatment of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04249583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*